Advertisement

Topics

Clinical Trials About "Novartis Canakinumab ACZ885 Reduced Cardiovascular Risk Subgroup CANTOS" RSS

21:39 EST 11th December 2018 | BioPortfolio

We list hundreds of Clinical Trials about "Novartis Canakinumab ACZ885 Reduced Cardiovascular Risk Subgroup CANTOS" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Novartis Canakinumab ACZ885 Reduced Cardiovascular Risk Subgroup CANTOS" on BioPortfolio

We have published hundreds of Novartis Canakinumab ACZ885 Reduced Cardiovascular Risk Subgroup CANTOS news stories on BioPortfolio along with dozens of Novartis Canakinumab ACZ885 Reduced Cardiovascular Risk Subgroup CANTOS Clinical Trials and PubMed Articles about Novartis Canakinumab ACZ885 Reduced Cardiovascular Risk Subgroup CANTOS for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Novartis Canakinumab ACZ885 Reduced Cardiovascular Risk Subgroup CANTOS Companies in our database. You can also find out about relevant Novartis Canakinumab ACZ885 Reduced Cardiovascular Risk Subgroup CANTOS Drugs and Medications on this site too.

Showing "Novartis Canakinumab ACZ885 Reduced Cardiovascular Risk Subgroup CANTOS" Clinical Trials 1–25 of 18,000+

Extremely Relevant

Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated Hs-CRP

The proposed study is a sub-study of the CANTOS trial (A randomized, double-blind, placebo-controlled, event driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP [CACZ885M2301]). The study proposes to perform serial Cardiopulmonary Exercise Tests (CPX) to prospectively measure changes in aerobic exercise capacity in patients with prior MI, elevated C reactive...


Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients

This 8-week study is designed to determine the target dose of canakinumab (ACZ885) for the management of acute flare in gout patients who are contraindicated to Non-Steroidal anti-inflammatory drugs and/or colchicine. The efficacy of ACZ885 will be compared to the corticosteroid triamcinolone acetonide.

Long Term Study of Canakinumab (ACZ885) in Patients With Gout

This 24-week open-label extension study is designed to provide additional long-term safety data up to a total of 1-year for patients rolling over from the core study, and to collect further efficacy and tolerability data for all the patients, irrespective whether they have an acute flare of gout or not. Patients will be treated on demand with canakinumab (ACZ885) in this extension study.


An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes

The primary objective of this study is to evaluate safety and tolerability of ACZ885 in this extension study. This extension study offers the opportunity for patients who completed Epoch 4 of the preceding CACZ885N2301 study to continue to be treated with ACZ885 until approval in Japan of the drug in Periodic Fever Syndromes or until development of ACZ885 in Periodic Fever Syndromes is suspended.

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis

The purpose of this study is to assess if ACZ885 will improve lung function in association with reduction of tissue inflammation in patients with chronic sarcoidosis.

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

This study will evaluate the effect of ACZ885 on vascular function in patients with documented atherosclerotic disease and T2DM or IGT.

Safety, Tolerability and Efficacy of ACZ885 (Canakinumab) in Patients With Active Rheumatoid Arthritis

This study will assess the safety, tolerability and efficacy of ACZ885 (an antibody) over a period of 2 yrs in patients with active rheumatoid arthritis.

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine

The purpose of this second extension study is to collect long-term safety and tolerability data and additional efficacy data in patients who are treated on demand upon flare with canakinumab.

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine

The purpose of this extension study is to collect additional safety, tolerability and efficacy data in patients who have completed the core study CACZ885H2357 to support the registration of canakinumab for the indication of gout.

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

This study will assess the initial efficacy and safety of canakinumab over a 4 week period in patients with SJIA having a flare. Response to treatment will be according to the adapted ACR Pediatric 30 criteria at Day 15.

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

To determine the effect of canakinumab versus placebo on daily pain experienced by sickle cell anemia patients (Reduction of average daily pain VAS over the period of Week 8 to 12 as compared to baseline levels).

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicines.

The purpose of this study is to demonstrate that canakinumab given upon acute gout flares relieves the signs and symptoms and prevents recurrence of gout flares in patients with frequent flares of gout for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffective. The efficacy of canakinumab will be compared to the corticosteroid triamcinolone acetonide

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine

The purpose of this study is to demonstrate that canakinumab given upon acute gout flares relieves the signs and symptoms and prevents recurrence of gout flares in patients with frequent flares of gout for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffective. The efficacy of canakinumab will be compared to the corticosteroid triamcinolone acetonide

To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee

The study will determine whether the ability of canakinumab to inhibit IL-1β activity for sustained time-periods with a favorable impact on the three critical parameters of OA symptoms, namely 1) pain 2) function and 3) stiffness. These outcomes will be compared to placebo.

Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis

This 12-week study is designed to evaluate risk-benefit of three subcutaneous dose regimens of ACZ885, added on to stable methotrexate (MTX) therapy (greater than or equal to 7.5 mg/week), compared to placebo in patients with active rheumatoid arthritis (RA). The study will investigate the magnitude of effect as well as onset of effect for the different dose regimens.

Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms

This study will investigate the clinical efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ACZ885, administered intravenously and subcutaneously to patients with NALP3 mutations whose clinical symptoms are either untreated or insufficiently treated and require medical intervention.

Relevant

Efficacy and Safety of a Single Dose of ACZ885 in Hospitalized Patients With Acute Gout

This is an exploratory proof-of-concept study to evaluate the safety and efficacy of ACZ885 for inflammation and pain associated with acute gouty arthritis.

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

This is a four month dose ranging study followed by a 24 to 48 month extension at the selected dose to characterize the safety and efficacy of the injectable IL-1B (interleukin 1, beta) antagonist canakinumab in the treatment of patients with Type 2 diabetes mellitus (T2DM) already treated on maximum dose metformin.

Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes

Canakinumab is a fully human anti-interleukin-1β (anti-IL-1β) monoclonal antibody (IgG-1 class). Canakinumab is designed to bind to human IL-1β and to functionally neutralize the bioactivity of this pro-inflammatory cytokine. The study is a two-group, multicenter, randomized, double-masked, placebo-controlled clinical trial. 108 subjects will be randomly assigned to receive either monthly subcutaneous injections of 2.0 mg/kg Canakinumab, or placebo for 12 months. All grou...

Evaluation of Novartis Access; a Non-communicable Disease (NCD) Access Initiative

Countries throughout the world are facing a growing non-communicable disease (NCD) burden. In developing countries, medicines to treat NCDs are often difficult to access or too expensive for many households. Novartis/Sandoz has recently launched Novartis Access, an initiative to subsidize a basket of NCD medicines sold to purchasers in program countries and delivered through the public and non-profit health sectors. This study will evaluate the impact of Novartis Access on the ...

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine

The purpose of this extension study is to collect additional safety, tolerability and efficacy data in patients who have completed the core study CACZ885H2356.

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With Methotrexate

This study assessed the long-term safety and tolerability of ACZ885 in patients with rheumatoid arthritis, as well as long-term efficacy, long-term preservation and/or improvement of joint structure and bone mineral density, and long term maintenance of health-related quality of life.

Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease

The purpose of this trial is to evaluate whether, in Intravenous Immunoglobulin-naïve or refractory patients diagnosed with active Kawasaki disease, administration of canakinumab controls fever and acute phase reactants.

Health and Cardiovascular Risk Factors in Slums.

Cardiovascular risk factors and disease burden has been showed to affect more deeply to poorer populations. People who live in slums are the most vulnerable subgroup in the populations where, paradoxically scarcity of data exists on risk factors and cardiovascular disease burden. Our study aim to describe the prevalence of cardiovascular risk factors and cardiovascular disease burden in a representative sample of an urban slum of Buenos Aires city, using validated questi...

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

This is a Phase Ib, open label, dose escalation study of spartalizumab + LAG525 in combination with NIR178, capmatinib, MCS110, or canakinumab, followed by a dose expansion in adult patients with advanced or metastatic TNBC. During the dose-escalation part of each treatment arm, patients will be treated with fixed doses of spartalizumab + LAG525 in combination with partner investigational drugs to be escalated until the MTD is reached or a lower RDE is established: NIR178, cap...


More From BioPortfolio on "Novartis Canakinumab ACZ885 Reduced Cardiovascular Risk Subgroup CANTOS"

Advertisement
Quick Search
Advertisement
Advertisement